These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 20154269)
21. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559 [TBL] [Abstract][Full Text] [Related]
22. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells. Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100 [TBL] [Abstract][Full Text] [Related]
23. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302 [TBL] [Abstract][Full Text] [Related]
24. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Jiang M; Huang O; Zhang X; Xie Z; Shen A; Liu H; Geng M; Shen K Molecules; 2013 Jan; 18(1):701-20. PubMed ID: 23299550 [TBL] [Abstract][Full Text] [Related]
25. Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Lahiry L; Saha B; Chakraborty J; Adhikary A; Mohanty S; Hossain DM; Banerjee S; Das K; Sa G; Das T Carcinogenesis; 2010 Feb; 31(2):259-68. PubMed ID: 19969555 [TBL] [Abstract][Full Text] [Related]
26. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Raha P; Thomas S; Thurn KT; Park J; Munster PN Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915 [TBL] [Abstract][Full Text] [Related]
27. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235 [TBL] [Abstract][Full Text] [Related]
28. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985 [TBL] [Abstract][Full Text] [Related]
29. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells. Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986 [TBL] [Abstract][Full Text] [Related]
30. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts. Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930 [TBL] [Abstract][Full Text] [Related]
31. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. van Agthoven T; Godinho MF; Wulfkuhle JD; Petricoin EF; Dorssers LC Int J Cancer; 2012 Nov; 131(9):1998-2007. PubMed ID: 22328489 [TBL] [Abstract][Full Text] [Related]
33. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. Lewis JS; Meeke K; Osipo C; Ross EA; Kidawi N; Li T; Bell E; Chandel NS; Jordan VC J Natl Cancer Inst; 2005 Dec; 97(23):1746-59. PubMed ID: 16333030 [TBL] [Abstract][Full Text] [Related]
34. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698 [TBL] [Abstract][Full Text] [Related]
35. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135 [TBL] [Abstract][Full Text] [Related]
36. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041 [TBL] [Abstract][Full Text] [Related]
37. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439 [TBL] [Abstract][Full Text] [Related]
38. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. Clarke R; Shajahan AN; Riggins RB; Cho Y; Crawford A; Xuan J; Wang Y; Zwart A; Nehra R; Liu MC J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):8-20. PubMed ID: 19444933 [TBL] [Abstract][Full Text] [Related]
39. Increase in hyaluronic acid degradation decreases the expression of estrogen receptor alpha in MCF7 breast cancer cell line. Hanoux V; Eguida J; Fleurot E; Levallet J; Bonnamy PJ Mol Cell Endocrinol; 2018 Nov; 476():185-197. PubMed ID: 29753772 [TBL] [Abstract][Full Text] [Related]
40. Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Oida K; Matsuda A; Jung K; Xia Y; Jang H; Amagai Y; Ahn G; Nishikawa S; Ishizaka S; Jensen-Jarolim E; Matsuda H; Tanaka A Sci Rep; 2014 Feb; 4():4057. PubMed ID: 24531845 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]